2011 San Antonio Breast Cancer Symposium....

Omaz

cp418 - 

Moderators

SABCS: Addition of Everolimus Helps Slow Breast Cancer
December 7, 2011
New information from the BOLERO-2 study shows that women diagnosed with hormone-receptor-positive, HER2-negative advanced-stage or metastatic breast cancer who got Afinitor and Aromasin in combination lived more than twice as long without the cancer growing than women who got only Aromasin. Read more...

Moderators

SABCS: Novel Agent Helps Slow Advanced Breast Cancer
December 8, 2011
Research suggests that adding the experimental medicine Omnitarg to a combination of Herceptin and Taxotere slows the growth of metastatic HER2-positive breast cancer more than Herceptin and Taxotere alone. Read more...

Moderators

SABCS: Hormone Combo Slows Metastatic Breast Cancer
December 8, 2011
A study has found that postmenopausal women diagnosed with hormone-receptor-positive metastatic breast cancer and treated with a combination of Arimidex and Faslodex as the first treatment for metastatic disease lived 6 months longer than women treated only with Arimidex. Read more...

Moderators

SABCS: Limiting Radiation Increases Mastectomies
December 6, 2011
Results from a large study suggest that brachytherapy may not be as effective as whole-breast radiation therapy at preventing breast cancer recurrence. Read more...

Moderators

SABCS: Bevacizumab Slows Metastatic Breast Cancer
December 8, 2011
A study has found that adding Avastin to a combination of Herceptin and Taxotere increased the likelihood of responding to treatment and the time women diagnosed with locally advanced and metastatic HER2-positive breast cancer lived without the cancer growing compared to women treated with only Herceptin and Taxotere. Read more...

Moderators

SABCS: Surgery May Help in Advanced Breast Cancer
December 9, 2011
A small study has found that women diagnosed with metastatic breast cancer (with no previous history of early-stage breast cancer) who had surgery to remove the primary tumor in the breast lived longer after diagnosis than women who didn't have the primary tumor removed. Read more...

Sherryc

MOderators the above link does not work.  Can you try to fix it I would like to read the article.

Moderators

Sorry about that Sherryc! Links should work now...

Moderators

SABCS: BRCA Carries Wider Disease Risk
December 9, 2011
Research shows that women with an abnormal BRCA1 or BRCA2 gene who've been diagnosed with breast cancer have a higher risk of being diagnosed with a new, different cancer in the opposite breast compared to women without an abnormal BRCA1 or BRCA2 gene. Read more...

Moderators

SABCS: Removing Ovaries May Put Bone Health at Risk
December 9, 2011
Research suggests that premenopausal women who have preventive oophorectomy to reduce breast cancer risk may be more likely to have low bone mineral density and arthritis. Read more...

Moderators

SABCS: Everolimus No Boon for Refractory HER2-Negative Disease
December 11, 2011
Research has found that adding Afinitor to paclitaxel didn't improve the response to neoadjuvant treatment with paclitaxel in women diagnosed with advanced-stage, HER2-negative breast cancer. Read more...

Moderators

SABCS: Bone Drug Gives DFS Boost in Breast Cancer
December 10, 2011
Results from three studies all suggest that Zometa can help reduce the risk of cancer recurrence when it's started right after surgery to treat hormone-receptor-positive early-stage breast cancer in postmenopausal and older premenopausal women. Read more...

Moderators

SABCS: Liposomal Doxorubicin Safe in Advanced Breast Cancer
December 12, 2011
A small study suggests that a new formulation of the chemotherapy medicine doxorubicin may be safer for the heart than traditional formulations. Read more...

Moderators

SABCS: Oral Bone Drugs Fail Breast Cancer Test
December 12, 2011
Two studies found that two oral bisphosphonates didn't reduce recurrence risk for women diagnosed with early-stage breast cancer. Read more...

cycle-path

Mods, the summary of the last article states that Boniva is an oral medication. There are two Bonivas: one is oral and one is IV. The original article doesn't seem to make clear which was given. I guess I'm not sure that the headline that "Oral Bone Drugs" didn't help is correct, since it's possible the trial participants were given IV Boniva.

Moderators

Thanks Cycle-path for your diligence. We'll look into this and get back to you.

Moderators

SABCS: Diabetes, Obesity Ups Risk of Breast Cancer
December 6, 2011
A very large study has found links between higher breast cancer risk and diabetes and obesity. Read more...

Moderators

Hi again Cycle-Path -- you are correct, Boniva can be given intravenously as well as orally. This study however, focuses on the oral form of the drug. We've made edits to the BCO commentary to make it more clear, which you can see here: http://www.breastcancer.org/tips/new_research/20111212.jsp. 

Thanks again for your good eye!

--The Mods